Prevalence and risk factors for metabolic syndrome in schizophrenia, schizoaffective, and bipolar disorder

References

• Almuhairi, S. J. (2023). Prevalence of metabolic syndrome and it’s associated factors in Emirati adults: The UAE healthy future cohort study. Al-Ain, United Arab Emirates: United Arab Emirates University.
   Google Scholar
• Alosaimi, F. D., Abalhassan, M., Alhaddad, B., Alzain, N., Fallata, E., Alhabbad, A., & Alassiry, M. Z. (2017). Prevalence of metabolic syndrome and its components among patients with various psychiatric diagnoses and treatments: A cross-sectional study. General Hospital Psychiatry, 45, 62–69. https://doi.org/10.1016/j.genhosppsych.2016.12.007
   PubMed Web of Science ®Google Scholar
• Amare, A. T., Schubert, K. O., Klingler-Hoffmann, M., Cohen-Woods, S., & Baune, B. T. (2017). The genetic overlap between mood disorders and cardiometabolic diseases: A systematic review of genome wide and candidate gene studies. Translational Psychiatry, 7(1), e1007. https://doi.org/10.1038/tp.2016.261
   PubMedGoogle Scholar
• Bener, A., Al-Hamaq, A. O. A. A., & Dafeeah, E. E. (2014). A two-fold risk of metabolic syndrome in a sample of patients with schizophrenia: Do consanguinity and family history increase risk? Diabetes & Metabolic Syndrome, 8 (1), 24–29. https://doi.org/10.1016/j.dsx.2013.10.003
   PubMedGoogle Scholar
• Bentley-Lewis, R., Koruda, K., & Seely, E. W. (2007). The metabolic syndrome in women. Nature Clinical Practice. Endocrinology & Metabolism, 3(10), 696–704. https://doi.org/10.1038/ncpendmet0616
   PubMedGoogle Scholar
• Bloomgarden, Z. T. (2003). American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25–26 August 2002, Washington, DC. Diabetes Care, 26(3), 933–939. https://doi.org/10.2337/diacare.26.3.933
   PubMedGoogle Scholar
• Bunevicius, R., & Prange, A. J.Jr. (2010). Thyroid disease and mental disorders: Cause and effect or only comorbidity? Current Opinion in Psychiatry, 23(4), 363–368. https://doi.org/10.1097/YCO.0b013e3283387b50
   PubMed Web of Science ®Google Scholar
• Cornier, M. A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008). The metabolic syndrome. Endocrine Reviews, 29(7), 777–822. https://doi.org/10.1210/er.2008-0024
   PubMed Web of Science ®Google Scholar
• el-Rufaie, O. E., & Absood, G. H. (1993). Minor psychiatric morbidity in primary health care: Prevalence, nature and severity. The International Journal of Social Psychiatry, 39(3), 159–166. https://doi.org/10.1177/002076409303900302
   PubMedGoogle Scholar
• Gami, A. S., Witt, B. J., Howard, D. E., Erwin, P. J., Gami, L. A., Somers, V. K., & Montori, V. M. (2007). Metabolic syndrome and risk of incident cardiovascular events and death. A systematic review and meta-analysis of longitudinal studies. Journal of the American College of Cardiology, 49(4), 403–414. https://doi.org/10.1016/j.jacc.2006.09.032
   PubMed Web of Science ®Google Scholar
• Grover, S., Malhotra, N., Chakrabarti, S., & Kulhara, P. (2012). Metabolic syndrome in bipolar disorders. Indian Journal of Psychological Medicine, 34(2), 110–118. https://doi.org/10.4103/0253-7176.101767
   PubMedGoogle Scholar
• Grundy, S. M., Hansen, B., Smith, S. C.Jr., Cleeman, J. I., & Kahn, R. A. (2004). Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(2), e19–e24. https://doi.org/10.1161/01.ATV.0000112379.88385.67
   PubMed Web of Science ®Google Scholar
• Hammoudeh, S., Ghuloum, S., Mahfoud, Z., Yehya, A., Abdulhakam, A., Al-Mujalli, A., Al-Zirie, M., Abdel Rahman, M. O., Godwin, A., Younes, N., Hani, Y., Mook-Kanamori, D., Mook-Kanamori, M., El Sherbiny, R., & Al-Amin, H. (2018). The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: A cross sectional comparative study. BMC Psychiatry, 18(1), 81. https://doi.org/10.1186/s12888-018-1662-6
   PubMedGoogle Scholar
• Harrow, M., Grossman, L. S., Herbener, E. S., & Davies, E. W. (2000). Ten-year outcome: Patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. The British Journal of Psychiatry: The Journal of Mental Science, 177(5), 421–426. https://doi.org/10.1192/bjp.177.5.421
   PubMedGoogle Scholar
• Henderson, D. C., Vincenzi, B., Andrea, N. V., Ulloa, M., & Copeland, P. M. (2015). Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. The Lancet. Psychiatry, 2(5), 452–464. https://doi.org/10.1016/S2215-0366(15)00115-7
   PubMed Web of Science ®Google Scholar
• Honer, W. G., MacEwan, G. W., Gendron, A., Stip, E., Labelle, A., Williams, R., & Eriksson, H. (2012). A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. The Journal of Clinical Psychiatry, 73(1), 13–20. https://doi.org/10.4088/JCP.10m06194
   PubMed Web of Science ®Google Scholar
• Kilbourne, A. M., Brar, J. S., Drayer, R. A., Xu, X., & Post, E. P. (2007). Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics, 48(5), 412–417. https://doi.org/10.1176/appi.psy.48.5.412
   PubMed Web of Science ®Google Scholar
• Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353(12), 1209–1223. https://doi.org/10.1056/NEJMoa051688
   PubMed Web of Science ®Google Scholar
• Mahmoud, I., & Sulaiman, N. (2021). Prevalence of metabolic syndrome and associated risk factors in the United Arab Emirates: A cross-sectional population-based study. Frontiers in Public Health, 9, 811006. https://doi.org/10.3389/fpubh.2021.811006
   PubMed Web of Science ®Google Scholar
• Malan-Müller, S., Kilian, S., van den Heuvel, L. L., Bardien, S., Asmal, L., Warnich, L., Emsley, R. A., Hemmings, S. M., & Seedat, S. (2016). A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia. Schizophrenia Research, 170(1), 1–17. https://doi.org/10.1016/j.schres.2015.11.011
   PubMed Web of Science ®Google Scholar
• McKnight, R. F., Adida, M., Budge, K., Stockton, S., Goodwin, G. M., & Geddes, J. R. (2012). Lithium toxicity profile: A systematic review and meta-analysis. Lancet, 379(9817), 721–728. https://doi.org/10.1016/S0140-6736(11)61516-X
   PubMed Web of Science ®Google Scholar
• Meyer, J. M., Davis, V. G., Goff, D. C., McEvoy, J. P., Nasrallah, H. A., Davis, S. M., Rosenheck, R. A., Daumit, G. L., Hsiao, J., Swartz, M. S., Stroup, T. S., & Lieberman, J. A. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophrenia Research, 101(1–3), 273–286. https://doi.org/10.1016/j.schres.2007.12.487
   PubMed Web of Science ®Google Scholar
• Mitchell, A. J., Lord, O., & Malone, D. (2012). Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: Meta-analysis. The British Journal of Psychiatry: The Journal of Mental Science, 201(6), 435–443. https://doi.org/10.1192/bjp.bp.111.094532
   PubMed Web of Science ®Google Scholar
• Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013). Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders–A systematic review and meta-analysis. Schizophrenia Bulletin, 39(2), 306–318. https://doi.org/10.1093/schbul/sbr148
   PubMed Web of Science ®Google Scholar
• Moteshafi, H., & Stip, E. (2012). Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: A meta-analysis. Expert Opinion on Drug Safety, 11(5), 713–732. https://doi.org/10.1517/14740338.2012.712682
   PubMed Web of Science ®Google Scholar
• Mukherjee, S., Skrede, S., Milbank, E., Andriantsitohaina, R., López, M., & Fernø, J. (2021). Understanding the effects of antipsychotics on appetite control. Frontiers in Nutrition, 8, 815456. https://doi.org/10.3389/fnut.2021.815456
   PubMed Web of Science ®Google Scholar
• Penninx, B. W. J. H., & Lange, S. M. M. (2018). Metabolic syndrome in psychiatric patients: Overview, mechanisms, and implications. Dialogues in Clinical Neuroscience, 20(1), 63–73. https://doi.org/10.31887/DCNS.2018.20.1/bpenninx
   PubMed Web of Science ®Google Scholar
• Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., Beck, K., Natesan, S., Efthimiou, O., Cipriani, A., & Howes, O. D. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. The Lancet. Psychiatry, 7(1), 64–77. https://doi.org/10.1016/S2215-0366(19)30416-X
   PubMed Web of Science ®Google Scholar
• Pradhan, A. D. (2014). Sex differences in the metabolic syndrome: Implications for cardiovascular health in women. Clinical Chemistry, 60(1), 44–52. https://doi.org/10.1373/clinchem.2013.202549
   PubMed Web of Science ®Google Scholar
• Ramezankhani, A., Azizi, F., & Hadaegh, F. (2022). Gender differences in changes in metabolic syndrome status and its components and risk of cardiovascular disease: A longitudinal cohort study. Cardiovascular Diabetology, 21(1), 227. https://doi.org/10.1186/s12933-022-01665-8
   PubMed Web of Science ®Google Scholar
• Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 123(2–3), 225–233. https://doi.org/10.1016/j.schres.2010.07.012
   PubMed Web of Science ®Google Scholar
• Sauerzopf, U., Weidenauer, A., Dajic, I., Bauer, M., Bartova, L., Meyer, B., Nics, L., Philippe, C., Pfaff, S., Pichler, V., Mitterhauser, M., Wadsak, W., Hacker, M., Kasper, S., Lanzenberger, R., Pezawas, L., Praschak-Rieder, N., & Willeit, M. (2021). Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia. Neuroimage. Clinical, 32, 102813. https://doi.org/10.1016/j.nicl.2021.102813
   PubMed Web of Science ®Google Scholar
• Scigliano, G., & Ronchetti, G. (2013). Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: A novel mechanistic hypothesis. CNS Drugs, 27(4), 249–257. https://doi.org/10.1007/s40263-013-0054-1
   PubMed Web of Science ®Google Scholar
• Shahda, M., Elsayed, O., & El-Boraie, A. (2010). Study of the prevalence of metabolic syndrome among psychiatric patients and its correlation with diagnosis and medications. Egyptian Journal of Psychiatry, 31(2), 17–24.
   Google Scholar
• Tian, Y., Wang, D., Wei, G., Wang, J., Zhou, H., Xu, H., Dai, Q., Xiu, M., Chen, D., Wang, L., & Zhang, X. Y. (2021). Prevalence of obesity and clinical and metabolic correlates in first-episode schizophrenia relative to healthy controls. Psychopharmacology, 238 (3), 745–753. https://doi.org/10.1007/s00213-020-05727-1
   PubMed Web of Science ®Google Scholar
• Tirupati, S., & Chua, L. E. (2007). Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists, 15(6), 470–473. https://doi.org/10.1080/10398560701636906
   PubMed Web of Science ®Google Scholar
• van Rossum, E. F., Koper, J. W., Huizenga, N. A., Uitterlinden, A. G., Janssen, J. A., Brinkmann, A. O., Grobbee, D. E., de Jong, F. H., van Duyn, C. M., Pols, H. A., & Lamberts, S. W. (2002). A polymorphism in the glucocorticoid receptor gene, which decreases sensitivity to glucocorticoids in vivo, is associated with low insulin and cholesterol levels. Diabetes, 51(10), 3128–3134. https://doi.org/10.2337/diabetes.51.10.3128
   PubMed Web of Science ®Google Scholar
• Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., Rosenbaum, S., & Correll, C. U. (2015). Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: A systematic review and meta-analysis. World Psychiatry, 14(3), 339–347. https://doi.org/10.1002/wps.20252
   PubMed Web of Science ®Google Scholar
• Vancampfort, D., Vansteelandt, K., Correll, C. U., Mitchell, A. J., De Herdt, A., Sienaert, P., Probst, M., & De Hert, M. (2013). Metabolic syndrome and metabolic abnormalities in bipolar disorder: A meta-analysis of prevalence rates and moderators. The American Journal of Psychiatry, 170(3), 265–274. https://doi.org/10.1176/appi.ajp.2012.12050620
   PubMed Web of Science ®Google Scholar
• Verhaegen, A. A., & Van Gaal, L. F. (2000). Drugs that affect body weight, body fat distribution, and metabolism. In K. R. Feingold, B. Anawalt, M. R. Blackman, A. Boyce, G. Chrousos, E. Corpas, W. W. de Herder, K. Dhatariya, K. Dungan, J. Hofland, S. Kalra, G. Kaltsas, N. Kapoor, C. Koch, P. Kopp, M. Korbonits, C. S. Kovacs, W. Kuohung, B. Laferrère, …, D. P. Wilson (Eds.), Endotext [Internet]. MDText.com, Inc.
   Google Scholar
• Vona, R., Gambardella, L., & Straface, E. (2018). Gender-associated biomarkers in metabolic syndrome. Intech Open. https://doi.org/10.5772/intechopen.81103
   Google Scholar
• World Health Organization (1992). The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Author.
   Google Scholar
• World Population Review (2023). United Arab Emirates population 2021. Retrieved March 27, 2023, from http://worldpopulationreview.com/countries/united-arab-emirates-population/
   Google Scholar
• Zhornitsky, S., Potvin, S., Moteshafi, H., Dubreucq, S., Rompré, P. P., & Stip, E. (2011). Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: A systematic review of the placebo-controlled monotherapy and add-on trials. International Clinical Psychopharmacology, 26(4), 183–192. https://doi.org/10.1097/YIC.0b013e3283430a0e
   PubMed Web of Science ®Google Scholar